Literature DB >> 23730215

Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor.

Bin Shi1, Deeksha Vishwamitra, J Gabrielle Granda, Thomas Whitton, Ping Shi, Hesham M Amin.   

Abstract

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is aberrantly expressed in a subset of T cell lymphoma that commonly affects children and young adults. NPM-ALK possesses significant oncogenic potential that was previously documented using in vitro and in vivo experimental models. The exact mechanisms by which NPM-ALK induces its effects are poorly understood. We have recently demonstrated that NPM-ALK is physically associated with type I insulin-like growth factor receptor (IGF-IR). A positive feedback loop appears to exist between NPM-ALK and IGF-IR through which these two kinases interact to potentiate their effects. We have also found that a single mutation of the Tyr(644) or Tyr(664) residue of the C terminus of NPM-ALK to phenylalanine decreases significantly, but does not completely abolish, the association between NPM-ALK and IGF-IR. The purpose of this study was to determine whether the dual mutation of Tyr(644) and Tyr(664) abrogates the association and interactions between NPM-ALK and IGF-IR. We also examined the impact of this dual mutation on the oncogenic potential of NPM-ALK. Our results show that NPM-ALK(Y644,664F) completely lacks association with IGF-IR. Importantly, we found that the dual mutation of Tyr(644) and Tyr(664) diminishes the oncogenic effects of NPM-ALK, including its ability to induce anchorage-independent colony formation and to sustain cellular transformation, proliferation, and migration. Furthermore, the association between NPM-ALK and IGF-IR through Tyr(644) and Tyr(664) appears to contribute to maintaining the stability of NPM-ALK protein. Our results provide novel insights into the mechanisms by which NPM-ALK induces its oncogenic effects through interactions with IGF-IR in this aggressive lymphoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23730215      PMCID: PMC3664999          DOI: 10.1593/neo.122012

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  63 in total

1.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts.

Authors:  C Sell; G Dumenil; C Deveaud; M Miura; D Coppola; T DeAngelis; R Rubin; A Efstratiadis; R Baserga
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

2.  Evidence for a differential interaction of SHC and the insulin receptor substrate-1 (IRS-1) with the insulin-like growth factor-I (IGF-I) receptor in the yeast two-hybrid system.

Authors:  S Tartare-Deckert; D Sawka-Verhelle; J Murdaca; E Van Obberghen
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

3.  Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.

Authors:  Daniel Cussac; Catherine Greenland; Serge Roche; Ren-Yuan Bai; Justus Duyster; Stephan W Morris; Georges Delsol; Michèle Allouche; Bernard Payrastre
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

4.  Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor.

Authors:  Y Jiang; J L Chan; C S Zong; L H Wang
Journal:  J Biol Chem       Date:  1996-01-05       Impact factor: 5.157

5.  Effect of a mutation at tyrosine 950 of the insulin-like growth factor I receptor on the growth and transformation of cells.

Authors:  M Miura; S Li; R Baserga
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

6.  Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein.

Authors:  Paolo Bonvini; Henry Dalla Rosa; Nadia Vignes; Angelo Rosolen
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

7.  Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain.

Authors:  S Li; A Ferber; M Miura; R Baserga
Journal:  J Biol Chem       Date:  1994-12-23       Impact factor: 5.157

8.  Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor.

Authors:  T DeAngelis; A Ferber; R Baserga
Journal:  J Cell Physiol       Date:  1995-07       Impact factor: 6.384

9.  Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5).

Authors:  J Fujimoto; M Shiota; T Iwahara; N Seki; H Satoh; S Mori; T Yamamoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor.

Authors:  D Coppola; A Ferber; M Miura; C Sell; C D'Ambrosio; R Rubin; R Baserga
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

View more
  10 in total

1.  Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.

Authors:  Zhiwei Huang; Zhijia Fang; Hong Zhen; Li Zhou; Hesham M Amin; Ping Shi
Journal:  Leuk Lymphoma       Date:  2014-02-17

2.  Cancer subclonal genetic architecture as a key to personalized medicine.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2013-12       Impact factor: 5.715

Review 3.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

4.  The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.

Authors:  Deeksha Vishwamitra; Choladda V Curry; Serhan Alkan; Yao-Hua Song; Gary E Gallick; Ahmed O Kaseb; Ping Shi; Hesham M Amin
Journal:  Mol Cancer       Date:  2015-02-25       Impact factor: 27.401

5.  The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.

Authors:  Suraj Konnath George; Deeksha Vishwamitra; Roxsan Manshouri; Ping Shi; Hesham M Amin
Journal:  Oncotarget       Date:  2014-07-30

6.  SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein.

Authors:  Deeksha Vishwamitra; Choladda V Curry; Ping Shi; Serhan Alkan; Hesham M Amin
Journal:  Neoplasia       Date:  2015-09       Impact factor: 5.715

7.  TrkA is a binding partner of NPM-ALK that promotes the survival of ALK+ T-cell lymphoma.

Authors:  Wenyu Shi; Suraj Konnath George; Bhawana George; Choladda V Curry; Albina Murzabdillaeva; Serhan Alkan; Hesham M Amin
Journal:  Mol Oncol       Date:  2017-06-18       Impact factor: 6.603

8.  Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma.

Authors:  Bhawana George; Suraj Konnath George; Wenyu Shi; Abedul Haque; Ping Shi; Ghazaleh Eskandari; Magnus Axelson; Olle Larsson; Ahmed O Kaseb; Hesham M Amin
Journal:  J Hematol Oncol       Date:  2019-07-24       Impact factor: 17.388

9.  Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.

Authors:  Francesca Megiorni; Heather P McDowell; Simona Camero; Olga Mannarino; Simona Ceccarelli; Milena Paiano; Paul D Losty; Barry Pizer; Rajeev Shukla; Antonio Pizzuti; Anna Clerico; Carlo Dominici
Journal:  J Exp Clin Cancer Res       Date:  2015-10-06

Review 10.  Type I insulin-like growth factor receptor signaling in hematological malignancies.

Authors:  Deeksha Vishwamitra; Suraj Konnath George; Ping Shi; Ahmed O Kaseb; Hesham M Amin
Journal:  Oncotarget       Date:  2017-01-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.